Tandem and Eli Lilly carried out trials to demonstrate the advantages of using Lyumjev in combination with Control-IQ ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

A series of case reports to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD), ...

Tandem Diabetes Care ( TNDM 4.25%) had some encouraging news to report on the regulatory front Thursday, and after it hit the ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...

The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive ...

A series of case reports to be presented at this year's Annual Meeting of The European Association for the Study of Diabetes ...

How can machine learning help individuals with type 1 diabetes (T1D)? This is what a study presented at this year’s Annual ...

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11.17 billion by 2032, from US$ 7.36 billion in 2023. The market is mainly driven by growth rate of diabetes ...

Senseonics (NYSE:SENS) is set to bring the longest-lasting continuous glucose monitor (CGM) to market following a major ...

Currently, they can deliver the insulin using an automated insulin delivery system or by taking a daily basal insulin injection and multiple mealtime insulin injections each day," Bergenstal ...